Orthopaedic Surgery

Molecular and Cellular Bone Biology Laboratory

Orthopaedic Surgery


Additional Information

Contact Us

Health Science Campus
Academic Assistance

attn: Tracy Jahns
MS #1094
Room 2448 Dowling Hall 
1125 Hospital Drive
Toledo, OH 43614
Phone: 419.383.6236
Fax: 419.383.3526


Recent publications

1. Lecka-Czernik B. Marrow fat metabolism is linked to the systemic energy metabolism. Bone 50:534-9, 2012.

2. Krings A, Rahman S, Huang S, Lu Y, Czernik PJ, Lecka-Czernik B. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 50:546-52, 2012.

3. Lecka-Czernik B. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs 13:793-801, 2010.

4. Lecka-Czernik B, Rosen CJ, Kawai M. Skeletal aging and the adipocyte program: New insights from an "old" molecule. Cell Cycle 9:3648-54, 2010.

5. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 8:178-184, 2010.

6. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, Ackert-Bicknell C, Garg N, Horowitz MC, Adamo ML, Clemmons DR, Rosen CJ. A
circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A 107:10508-13, 2010.

7. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 8:84-90, 2010.

8. Kawai M, Green CB, Horowitz M, Ackert-Bicknell C, Lecka-Czernik B, Rosen CJ. Nocturnin: a circadian target of Pparg-induced adipogenesis. Ann N Y Acad Sci. 1192:131-8, 2010.

9. Huang S., Kaw M., Harris M.T., Ebraheim N., McInerney M.F., Najjar S.M., Lecka-Czernik B. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 46:1138-45, 2010.

10. Lecka-Czernik B. Bone as a target for type 2 diabetes treatment. Current Opinion in Investigational Drugs 10:1085-90, 2009.

11. Shockley K.R., Lazarenko O.P., Czernik P.J., Rosen C.J., Churchill G.A., Lecka-Czernik B. PPARg2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232-46, 2009.

12. Ackert-Bicknell C.L., Skockley K.R., Horton L.G., Lecka-Czernik B., Churchill G.A., Rosen C.J. Strain specific effects of Rosiglitazone on bone mass, body composition and serum IGF-I. Endocrinology 150:1330-1340, 2009.

13. Lecka-Czernik B. Bone as an integral part of energy metabolism. J Musculoskeletal and Neuronal Interactions 8:345-346, 2008.

14. Lecka-Czernik B. Local and systemic functions of bone fat and its contribution to the energy metabolism – The effect of diabetes and obesity on bone. J Musculoskeletal and Neuronal Interactions 8:347-348, 2008.

15. Shockley K.R., Rosen C.J., Churchill G.A., Lecka-Czernik B.  PPARγ2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells. PPAR Res, Article ID 81219, 2007.

16. Ackert-Bicknell C.L., Salisbury J.L., Horowitz M., DeMambro V.E., Horton L.G., Shultz K.L., Lecka-Czernik B., Rosen C.J. A chromosomal inversion within a Quantitative Trait Locus has a major effect on adipogenesis and osteoblastogenesis. Ann NY Acad Sci 1116:291-305, 2007. 

17. Lazarenko O.P., Rzonca S.O., Hogue W.R., Suva L.J., Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-80, 2007.

18. Lecka-Czernik B., Ackert-Bicknell C.L., Adamo M., Marmolejos V., Churchill G.A., Shockley K.R., Reid I.R., Grey A., Rosen C.J.  Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo. Endocrinology 148:903-11, 2007.

19. Ranganathan G., Unal R., Pokrovskaya I., Yao-Borengasser A., Phanavanh B., Lecka-Czernik B., Rasouli N., Kern P. The lipogenic enzymes DGAT1, fatty acid synthetase, and lipoprotein lipase in adipose tissue: effects of obesity, insulin resistance, and treatment with thiazolidinediones. J Lipid Res 47:2444-50, 2006.

20. Lecka-Czernik B. PPARs and Bone Metabolism. PPAR Research, Article ID 18089, 2006.

21. Lecka-Czernik B., Suva L. Resolving the two “bony” faces of PPAR-g. PPAR Research: PPARs and Bone Metabolism. Article ID 27489. 2006.

22. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., Palermo L., Lecka-Czernik B., Feingold K.R., Strotmeyer E.S., Resnick H.E., Carbone L., Beamer B.A., Won Park S., Lane N.E., Harris T.B., Cummings S.R.  Thiazolidinedione (TZD) use and change in bone density in older diabetic adults. J Clin Endo Metab 91:3349-3354, 2006.

23. Lazarenko O.P., Rzonca S.O., Suva L.J., Lecka-Czernik B.  Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38:74-84, 2006.

Last Updated: 7/27/17